文献速递类风湿关节炎

真实世界环境中类风湿关节炎患者DMARDs的个体化减量

Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world setting.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

基于德国2018年7月至2021年3月的前瞻性对照队列研究,纳入持续缓解超过6个月的RA患者,比较基于共享决策的个体化减量(n=200)与未减量(n=237)患者的结局。个体化减量组与继续治疗组的病情复发风险和失去缓解风险均无统计学差异,减量组药物费用下降而继续治疗组上升。

要点

  • 个体化减量组与继续治疗组的病情复发风险(HR 0.88,95%CI 0.59,1.30)和失去缓解风险(HR 1.04,95%CI 0.73,1.49)无统计学差异。
  • 基线后12个月观察到疾病活动度轻度升高和生活质量轻度下降,两组间无统计学显著差异。
  • 个体化减量组药物费用下降1017€,继续治疗组上升1151€(P < 0.01)。

核心结论

  • DMARDs个体化减量不增加病情复发或失去缓解的平均风险。
  • 作者认为鼓励风湿科医生和患者在共享决策中应用减量可能是实现RA个体化治疗的一种可行方法。

研究设计与样本

  • 研究利用德国2018年7月至2021年3月开展的一项受控前瞻性队列研究的数据,结合病历与理赔数据。
  • 纳入入组时符合减量条件的持续缓解超过6个月的RA患者。
  • 基于共享决策的个体化减量组n=200,与无任何剂量减少的继续治疗组n=237进行比较。
  • 采用风险校正的Kaplan-Meier估计和Cox回归评估失去缓解风险与病情复发风险。
  • 基于德国一家大型疾病保险基金投保患者的理赔数据(n=76)评估基线前1年与基线后1年的费用差异。

主要发现

  • 个体化减量组与继续治疗组的病情复发风险(HR 0.88,95%CI 0.59,1.30)无统计学差异。
  • 个体化减量组与继续治疗组的失去缓解风险(HR 1.04,95%CI 0.73,1.49)无统计学差异。
  • 基线后12个月观察到疾病活动度轻度升高和生活质量轻度下降,两组间无统计学显著差异。
  • 个体化减量组药物费用下降1017€,继续治疗组药物费用上升1151€(P < 0.01)。

临床怎么用

  • 作者认为鼓励风湿科医生和患者在共享决策中应用减量可能是实现RA个体化治疗的一种可行方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aim to provide real-world evidence on the effectiveness of patient-individual tapering of DMARDs for patients with RA in daily clinical practice using medical records and claims data. METHODS: We utilize data obtained through a controlled prospective cohort study in Germany conducted from July 2018 to March 2021. Participants consist of RA patients in sustained remission (>6 months) who were eligible for tapering at enrolment. Patients treated with individual tapering based on shared decision making (n = 200) are compared with patients without any dose reduction (n = 237). The risk of loss of remission and the risk of flare is assessed with risk-adjusted Kaplan-Meier estimators and Cox regressions. We evaluate differences in costs 1 year before and after baseline based on claims data for the subgroup of patients insured at one major sickness fund in Germany (n = 76). RESULTS: The risk of flare (hazard ratio 0.88, 95% CI 0.59, 1.30) or loss of remission (hazard ratio 1.04, 95% CI 0.73, 1.49) was not statistically different between the individual tapering group and the continuation group. Minor increases of disease activity and decreases of quality of life were observed 12 months after baseline, again with no statistically significant difference. Drug costs decreased by 1017€ in the individual tapering group while they increased by 1151€ in the continuation group (P < 0.01). CONCLUSION: Individual tapering of DMARDs does not increase the average risk of experiencing flares or loss of remission. Encouraging rheumatologists and patients to apply tapering in shared decision making may be a feasible approach to allow individualization of treatment in RA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Birkner B, Rech J, Edelmann E, et al. Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world setting. Rheumatology (Oxford). 2023. PMID: 35980267. doi:10.1093/rheumatology/keac472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。